JP7065839B2 - 急性腎障害を処置する方法 - Google Patents
急性腎障害を処置する方法 Download PDFInfo
- Publication number
- JP7065839B2 JP7065839B2 JP2019518278A JP2019518278A JP7065839B2 JP 7065839 B2 JP7065839 B2 JP 7065839B2 JP 2019518278 A JP2019518278 A JP 2019518278A JP 2019518278 A JP2019518278 A JP 2019518278A JP 7065839 B2 JP7065839 B2 JP 7065839B2
- Authority
- JP
- Japan
- Prior art keywords
- acute
- compound
- pharmaceutical composition
- kidney injury
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| US62/404,390 | 2016-10-05 | ||
| PCT/US2017/055400 WO2018067857A1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533660A JP2019533660A (ja) | 2019-11-21 |
| JP2019533660A5 JP2019533660A5 (enExample) | 2020-10-22 |
| JP7065839B2 true JP7065839B2 (ja) | 2022-05-12 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518278A Active JP7065839B2 (ja) | 2016-10-05 | 2017-10-05 | 急性腎障害を処置する方法 |
Country Status (33)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016333963C1 (en) | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| US11358954B2 (en) * | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN109843857B (zh) * | 2016-10-05 | 2023-01-06 | 米托布里奇公司 | Ppar激动剂化合物的结晶和盐形式 |
| WO2021013772A1 (en) | 2019-07-19 | 2021-01-28 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CA3212825A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115813901B (zh) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505907A (ja) | 2003-09-19 | 2007-03-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物 |
| JP2012505905A (ja) | 2008-10-17 | 2012-03-08 | メタボレックス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| WO2015055694A1 (en) | 2013-10-15 | 2015-04-23 | Sanofi | 4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| WO2016057656A1 (en) | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| JP2016512201A (ja) | 2013-03-08 | 2016-04-25 | アッヴィ・インコーポレイテッド | 急性腎障害の治療方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006145872A (ru) * | 2004-05-25 | 2008-06-27 | Метаболекс, Инк. (Us) | Замещенные триазолы в качестве модуляторов ppar и способы их получения |
| RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| JP2016520552A (ja) * | 2013-04-05 | 2016-07-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Ｐｐａｒアゴニスト |
| CN110007084B (zh) * | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| AU2016333963C1 (en) * | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
-
2017
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
- 2017-10-05 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en not_active Ceased
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 MX MX2019003949A patent/MX387518B/es unknown
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Ceased
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh not_active IP Right Cessation
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en not_active Ceased
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
- 2017-10-05 SM SM20210111T patent/SMT202100111T1/it unknown
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 BR BR112019005539-8A patent/BR112019005539A2/pt not_active Application Discontinuation
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505907A (ja) | 2003-09-19 | 2007-03-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物 |
| JP2012505905A (ja) | 2008-10-17 | 2012-03-08 | メタボレックス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| JP2016512201A (ja) | 2013-03-08 | 2016-04-25 | アッヴィ・インコーポレイテッド | 急性腎障害の治療方法 |
| WO2015055694A1 (en) | 2013-10-15 | 2015-04-23 | Sanofi | 4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| WO2016057656A1 (en) | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109789117B (zh) | 治疗急性肾损伤的方法 | |
| CN104023723B (zh) | 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物 | |
| JP2003531856A (ja) | リン酸輸送阻害剤 | |
| CN112292125B (zh) | 蛋白尿的治疗 | |
| JP2023529691A (ja) | 慢性腎疾患を処置または防止するための方法 | |
| JP2018515454A (ja) | 尿酸輸送体阻害剤のナトリウム塩およびその結晶形 | |
| JP5290190B2 (ja) | イミダゾール−５−カルボン酸誘導体の塩、製造方法及びその医薬組成物 | |
| HK40008682B (en) | Methods of treating acute kidney injury | |
| HK40008682A (en) | Methods of treating acute kidney injury | |
| WO2024023696A1 (en) | Dosing regimen for a nlrp3 inhibitor | |
| EP4552642A1 (en) | Agent for reducing blood myostatin level | |
| JP2024513502A (ja) | Ｕｒａｔ１阻害剤、医薬組成物及びその使用 | |
| CN111303161B (zh) | 嘧啶并氮杂环类化合物及其用途 | |
| TW201927307A (zh) | 含有１，４－苯并硫氮呯－１－氧化物衍生物之光學異構物之腎功能障礙的改善藥 | |
| JP2002255937A (ja) | 新規化合物 | |
| CN116648445A (zh) | 治疗或预防慢性肾脏病的方法 | |
| WO2023225300A2 (en) | Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto | |
| CN103664930B (zh) | 一类含噻唑结构的化合物、其制备方法和用途 | |
| HK40096745A (en) | Methods for treating or preventing chronic kidney disease | |
| US20090281083A1 (en) | Combination Product | |
| JP2000086508A (ja) | ヒスタミン遊離抑制剤 | |
| JPS634807B2 (enExample) | ||
| JP2006036691A (ja) | 腎炎の治療または予防剤 | |
| JP2003238408A (ja) | 組織線維症の治療剤または予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20191218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191218 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20191220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200910 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200910 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210624 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210630 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211221 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220404 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220426 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7065839 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |